EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE
Report
- Report Number
- 2015691-2020-15303
- Event Type
- Injury
- Date Received
- December 28, 2020
- Date of Event
- December 1, 2020
- Report Date
- November 13, 2023
- Manufacturer
- EDWARDS LIFESCIENCES
- Product Code
- NPT
- PMA / PMN Number
- P140031
- Adverse Event
- Yes
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CH
- Reporter Occupation
- OTHER HEALTH CARE PROFESSIONAL
- Health Professional
- Yes
Narratives
CITATION: HONG, N. C., ET AL. ''TRANSCATHETER AORTIC VALVE REPLACEMENT WITH ANTEROGRADE GUIDE WIRE THROUGH ATRIAL SEPTUM IN 2 PATIENTS WITH SEVERE AORTIC STENOSIS POST TRANSCATHETER OR SURGICAL AORTIC VALVE REPLACEMENT.'' ZHONGHUA XIN XUE GUAN BING ZA ZHI 50.5 (2022): 509-511. CORRECTED B.7 AND D6A BASED ON INFORMATION DISCOVERED IN THE ARTICLE REFERENCED ABOVE.
UDI: (B)(4); INVESTIGATION IS ONGOING. THIS INDIVIDUAL REPORT PROVIDES DATA RECEIVED FROM THE THV/TVT REGISTRY.
AS REPORTED BY THE EDWARDS EUROPEAN AFFILIATE, 10 MONTHS AFTER IMPLANTATION OF A 20MM SAPIEN 3 VALVE, THE PATIENT BEGAN TO SUFFER FROM SEVERE ANGINA. CARDIAC ECHOCARDIOGRAPHY SHOWED AOV PEAK VELOCITY 430 CM/S, AOV PEAK GRADIENT 74 MMHG AND AOV MEAN GRADIENT OF 39 MMHG. PATIENT WAS HOSPITALIZED DUE TO CHEST PAIN. TREATMENT INVOLVED ANTICOAGULATION THERAPY, AS PHYSICIAN SUSPECTS VALVE THROMBOSIS AS ROOT CAUSE OF AORTIC VALVE STENOSIS. A VIV PROCEDURE WAS PERFORMED WITH A SELF-EXPANDABLE NON-EDWARDS VALVE. THROMBOSIS WAS CONFIRMED AS THE ROOT CAUSE AND THE PATIENT WAS IN GOOD CONDITION AND STABLE.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 1549382 | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE | AORTIC VALVE, PROSTHESIS, PERCUTANEOUSLY DELIVERED | NPT | EDWARDS LIFESCIENCES | 9600TFX20 | 5731788 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 | 73 YR | Unknown | Hospitalization| R |